Evidence map›Paper›PMID 41246854›Full record

ArticleEuropean journal of neurology2025

Novel Mutations in Titin Exon 363 With Different Phenotypes Including a Founder Mutation in Eastern Europe.

Veronica Sian, Maria Francesca Di Feo, Sergei Kurbatov, Anna Vihola, Helena Luque, Fedor Konovalov, Stojan Peric, Cathrina Duffy, Cornelia Kornblum, Kristl G Claeys and 3 more

Abstract readMulticenter Study
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Veronica SianFolkhälsan Research Center, Helsinki, Finland.ORCID 0000-0002-8670-744X
Maria Francesca Di FeoFolkhälsan Research Center, Helsinki, Finland.
Sergei KurbatovResearch Institute of Experimental Biology and Medicine, Voronezh State Medical University N.N. Burdenko, Voronezh, Russia.
Anna ViholaFolkhälsan Research Center, Helsinki, Finland.
Helena LuqueFolkhälsan Research Center, Helsinki, Finland.
Fedor KonovalovIndependent Clinical Bioinformatics Laboratory, Moscow, Russia.
Stojan PericNeurology Clinic, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.ORCID 0000-0002-2979-556X
Cathrina DuffyDepartment of Neuromuscular Diseases, Center for Neurology, University Hospital of Bonn, Bonn, Germany.
Cornelia KornblumDepartment of Neuromuscular Diseases, Center for Neurology, University Hospital of Bonn, Bonn, Germany.
Kristl G ClaeysDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-9937-443X
Peter HackmanFolkhälsan Research Center, Helsinki, Finland.
Bjarne UddFolkhälsan Research Center, Helsinki, Finland.
Marco SavareseFolkhälsan Research Center, Helsinki, Finland.

Funding

Academy of Finland 339437Academy of Finland 346209Academy of Finland 361979European Joint Program on Rare Diseases (project IDOLS-G)European Union (Compass-NMD) 101080874Samfundet Folkhälsan i Svenska FinlandSigrid Juséliuksen Säätiö 230217
6 · The paper itself

Abstract

backgroundTitin, the largest human protein, is essential for sarcomere structure and function. The TTN gene, spanning 364 exons, undergoes extensive alternative splicing thus producing multiple isoforms. The M-band region, encoded by exons 359-364, plays a critical role in sarcomere integrity and mechanical stability. Exon 363 is of interest due to its involvement in titinopathies. Pathogenic truncating variants in this exon have been linked to recessive myopathies, including and mainly young-onset recessive distal titinopathy.

methodsA multicenter study was conducted on six patients from five unrelated families with confirmed recessive titinopathy and truncating variants in exon 363. Clinical evaluations were performed. Genetic testing and segregation analysis confirmed the phase of the variants.

resultsA novel truncating variant c.107578C>T, p.(Gln35860Ter) was identified in four unrelated patients of Eastern European ancestry, all carrying a second pathogenic variant in a canonical TTN exon. These patients exhibited juvenile/young-adult onset recessive distal titinopathy with progressive lower limb weakness, frequently asymmetric muscle involvement, and no cardiac or respiratory complications. A Belgian family presented with a congenital myopathy caused by a novel frameshift deletion c.107430delA, p.(Ser35811AlafsTer32) in exon 363, in compound heterozygosity with a truncating variant in exon 208. These patients showed a more severe phenotype.

conclusionsThis study expands the spectrum of TTN-related myopathies, emphasizing exon 363's pathogenic significance. Truncating exon 363 variants contribute to young onset recessive distal and sometimes early onset titinopathy with contractures, and the phenotype severity is influenced by the second variant's location and exon usage.

Indexed as

ConnectinExonsFounder EffectMutationAdolescentAdultChildFemaleHumansMalePedigreePhenotypeYoung AdultConnectinTTN protein, humancongenital myopathyfounder mutationM‐bandrecessive distal myopathytitin

Identifiers

PMID41246854
PMCPMC12620988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.